OVARIAN CANCER and US: Opaxio

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label Opaxio. Show all posts
Showing posts with label Opaxio. Show all posts

Thursday, March 04, 2010

Gynecologic Oncology Group (GOG) Notifies CTI That Continuation of GOG-212 Pivotal Trial of OPAXIO Maintenance Therapy in Front Line Ovarian Cancer Remains High Priority - MarketWatch



press release

March 4, 2010, 1:30 a.m. EST
Gynecologic Oncology Group (GOG) Notifies CTI That Continuation of GOG-212 Pivotal Trial of OPAXIO Maintenance Therapy in Front Line Ovarian Cancer Remains High Priority
GOG-218 Bevacizumab Results Do Not Influence Importance of GOG-212


SEATTLE, March 4, 2010 /PRNewswire via COMTEX/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO(TM) used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial.

Tuesday, March 02, 2010

Opaxio (XYOTAX) - New FDA Date for Cell Therapeutics: media item



Note: Lots of unanswered questions

"....Meantime, Cell Therapeutics also disclosed another setback for its experimental cancer drug Opaxio. The Gynecologic Oncology Group (GOG) turned down Cell Therapeutics' request to conduct an interim analysis of the phase III study of Opaxio in patients with advanced ovarian cancer,